ABVC BioPharma, Inc (ABVC): Forward P/S Multiple

Graphic logo of ABVC BioPharma, Inc (ABVC)

ABVC BioPharma adheres to ESG principles by optimizing resources and utilizing recycled packaging in botanical medicine. This forward price-to-sales chart visualizes market expectation trends, where the 43.70 metric indicates the status of current capitalization. Business success relies on the licensing of ADHD and depression treatments via royalties. The company is currently preparing the results of Phase II trials for its innovative developments.

ABVC (abvcpharma.com) Price-to-Projected Revenue Ratio history from 07/04/2022 to 03/05/2026

Comprehensive metric breakdowns and analytics for ABVC BioPharma, Inc (ABVC)

- current price and projected stock value:
Stock Price ABVC BioPharma, Inc.|ABVC - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization ABVC BioPharma, Inc|ABVC - Total Company Value
- issuer book value statistics:
Accounting Value per Share ABVC BioPharma|ABVC - Company Book Value|Market Capitalization to Book Value Ratio abvcpharma.com|ABVC - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio ABVC BioPharma|ABVC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ABVC BioPharma|ABVC - Company Debts|Debts to Book Capitalization ABVC BioPharma, Inc|ABVC - Long-Term Debt Volume|Company Short-Term Debt ABVC BioPharma|Quick Liquidity abvcpharma.com
- net income and valuation multiples indicators:
ABVC - Profit After Tax|Projected Future Earnings ABVC BioPharma|ABVC - Company Value to Net Income|Forward P/E Multiple ABVC BioPharma Inc|ABVC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma, Inc|ABVC - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months ABVC BioPharma|ABVC - Net earnings per share for the last 12 months|Quarterly EPS earnings growth abvcpharma.com|ABVC - Earnings growth in current year|Earnings growth forecast for next year ABVC BioPharma
- sales revenue and business income indicators:
ABVC - Revenue and Sales Volume|Projected Sales Volume ABVC BioPharma, Inc.|ABVC - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple ABVC BioPharma, Inc
Summary company analytics:ABVC BioPharma, Inc. ABVC
Manufactured products of ABVC BioPharma, Inc

The forward P/S reflects the ratio of market capitalization to expected revenue, allowing for an assessment of the premium paid for potential sales growth. By analyzing the forward P/S metric, an investor can identify the risk of overvaluation for ABVC BioPharma, given the dependence of revenues on volatile licensing deals and the company's limited working capital liquidity.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|Verona Pharma Corp - Forward P/S Multiple|MENS: Price-to-Projected Revenue Ratio|LGND (Ligand Pharmaceuticals) - Forward Price-to-Revenue Multiple|AMRX (amneal.com) - Price-to-Projected Revenue Ratio|PRGO (Perrigo) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|GLPG (Galapagos Corp) - Forward Price to Sales|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|mannkindcorp.com - Price-to-Projected Revenue Ratio|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Theravance Corp (TBPH)|Price-to-Projected Revenue Ratio Aquestive Therapeutics|scPharma - Future Price to Revenue|Forward P/S Multiple TECX|TNXP (Tonix Pharma) - Forward Price to Sales|Forward P/S Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Forward P/S Multiple Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Price-to-Projected Revenue Ratio|Forward Price to Sales EXOZ (invizyne.com)|oramed.com (ORMP) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Entera Bio|HYFT (MindWalk) - Forward P/S Multiple|Forward P/S Multiple Cumberland Corp|Forward P/S Multiple QNTM|Forward P/S Multiple fibrogen.com (FGEN)|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings - Price-to-Projected Revenue Ratio|SNYR: Forward Price-to-Revenue Multiple|RLYB: Price-to-Projected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple pulmatrix.com|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Aptorum - Future Price to Revenue|Forward P/S Multiple LYRA|IBO (Impact BioMedical, Inc.) - Forward Price to Sales|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward P/S Multiple cbdMD Inc. YCBD|PRFX - Price-to-Projected Revenue Ratio|Forward Price to Sales CYTO (Altamira Therapeutics)|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OptiNose Corp|PIRS (Pieris Pharmaceuticals) - Forward P/S Multiple|Forward P/S Multiple procapsgroup.com|Forward Price-to-Revenue Multiple PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding Group) - Forward Price to Sales|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc (TFFP) - Market Cap to Future Revenue Ratio